^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PIT565

    i
    Other names: PIT565, PIT-565, PIT 565
    Associations

    News

    Trials
    Company:
    Novartis
    Drug class:
    CD3 agonist, CD19 inhibitor, CD2 agonist
    Related drugs:
    Associations

    News

    Trials
    1m
    An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE). (clinicaltrials.gov)
    P1, N=54, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PIT565
    1m
    An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis (clinicaltrials.gov)
    P1, N=57, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PIT565
    2ms
    An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE). (clinicaltrials.gov)
    P1, N=54, Recruiting, Novartis Pharmaceuticals | Trial completion date: Jul 2027 --> Nov 2027 | Trial primary completion date: Jul 2027 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    PIT565
    3ms
    An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE). (clinicaltrials.gov)
    P1, N=54, Recruiting, Novartis Pharmaceuticals | N=32 --> 54
    Enrollment change
    |
    PIT565
    5ms
    Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2028 --> May 2026 | Trial primary completion date: Jun 2027 --> May 2026
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    PIT565
    5ms
    Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, Novartis Pharmaceuticals | N=140 --> 61
    Enrollment change
    |
    CD19 positive
    |
    PIT565
    7ms
    Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=140, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD19 positive
    |
    PIT565
    1year
    An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis (clinicaltrials.gov)
    P1, N=57, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PIT565
    1year
    An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis (clinicaltrials.gov)
    P1, N=57, Not yet recruiting, Novartis Pharmaceuticals
    New P1 trial
    |
    PIT565
    over1year
    An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE). (clinicaltrials.gov)
    P1, N=54, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting | Trial completion date: Nov 2027 --> Jul 2027 | Trial primary completion date: Nov 2027 --> Jul 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    PIT565
    2years
    An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE). (clinicaltrials.gov)
    P1, N=54, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Jul 2028 --> Nov 2027 | Trial primary completion date: Jul 2028 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    PIT565
    over2years
    An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE). (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Novartis Pharmaceuticals
    New P1 trial
    |
    PIT565